Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

SOHO 2023 | VENICE II trial: health-related QoL in patients with CLL treated with venetoclax

Mary Ann Anderson • 8 Sep 2023

SOHO 2023

Chronic Lymphocytic Leukemia Leukemia Venetoclax

VENICE II

Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, Royal Melbourne Hospital, Melbourne, Australia, briefly discusses the Phase III VENICE II trial (NCT02980731) investigating the impact of venetoclax therapy on the quality of life (QoL) of patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Important factors to consider when selecting between venetoclax & BTK inhibitors for CLL

Mary Ann Anderson • 8 Sep 2023

Novel BCL-2 & BCL-2/BCLxL inhibitors emerging for the treatment of hematological malignancies

Mary Ann Anderson • 8 Sep 2023

Clonal evolution and resistance mechanisms to BCL-2 receptor inhibition

Mary Ann Anderson • 20 Sep 2019

iwCLL 2019 - facilitating the development of novel agents and treatment outcomes

Mary Ann Anderson • 21 Sep 2019

Related Videos

The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial

Felicitas Thol • 19 Apr 2024

Integrating genomics and MRD in transplant decision-making for patients with AML

Jurjen Versluis • 22 Apr 2024

Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL

Alberto Olaya-Vargas • 15 Apr 2024

Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS

Sridhar Chaganti • 16 Apr 2024